Sea sponge drug could boost advanced breast cancer survival by five extra months — ScienceDaily
Researchers led by Professor Chris Twelves, based at the University of Leeds and Leeds Teaching Hospitals NHS Trust, looked at two major clinical trials of more than 1,800 women with breast cancer that had started to spread to other parts of the body. The phase III trials — the final stage of testing before deciding whether a drug can be prescribed to patients — compared the survival of women treated with eribulin to those given standard treatment…